Cholangiocarcinoma: Molecular pathways and therapeutic opportunities

Seminars in Liver Disease

Volumn 34, Issue 4, 2014, Pages 456-464

  Rizvi, Sumera ^a   Borad, Mitesh J ^b   Patel, Tushar ^c   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

cholangiocarcinoma; molecular pathogenesis; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CHOLESTEROL; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; HISTONE DEACETYLASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 3; NOTCH RECEPTOR; OXYSTEROL; PHOSPHATIDYLINOSITOL 3 KINASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; ROS1 PROTEIN; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG; UNINDEXED DRUG; TUMOR MARKER;

ARTICLE; BILE DUCT CARCINOMA; BILE DUCT STONE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CELL STRUCTURE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLONORCHIASIS; DNA METHYLATION; DNA SEQUENCE; ENZYME ACTIVATION; GENE FUSION; GENE OVEREXPRESSION; HUMAN; LOSS OF FUNCTION MUTATION; NITROSATIVE STRESS; OPISTHORCHIASIS; OVERALL SURVIVAL; OXIDATION; OXIDATIVE STRESS; PERSONALIZED MEDICINE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; UPREGULATION; ANIMAL; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DRUG DESIGN; DRUG EFFECTS; GENETICS; INTRAHEPATIC BILE DUCT; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOMARKERS, TUMOR; CHOLANGIOCARCINOMA; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84949117556     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1394144     Document Type: Article

References (82)

1. Rizvi S., Gores G. J. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology: 2013; 145 6 1215 1229
2. Sirica A. E., Gores G. J. Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology: 2014; 59 6 2397 2402
3. Razumilava N., Gores G. J. Cholangiocarcinoma. Lancet: 2014; 383 9935 2168 2179
4. Farley D. R., Weaver A. L., Nagorney D. M. Natural history of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc: 1995; 70 5 425 429
5. Everhart J. E., Ruhl C. E. Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas. Gastroenterology: 2009; 136 4 1134 1144
6. Valle J., Wasan H., Palmer D. H., et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med: 2010; 362 14 1273 1281
7. Tyson G. L., El-Serag H. B. Risk factors for cholangiocarcinoma. Hepatology: 2011; 54 1 173 184
8. Jaiswal M., LaRusso N. F., Burgart L. J., Gores G. J. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res: 2000; 60 1 184 190
9. Jaiswal M., LaRusso N. F., Shapiro R. A., Billiar T. R., Gores G. J. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology: 2001; 120 1 190 199
10. Haigh W. G., Lee S. P. Identification of oxysterols in human bile and pigment gallstones. Gastroenterology: 2001; 121 1 118 123
11. Kuver R. Mechanisms of oxysterol-induced disease: insights from the biliary system. Clin Lipidol: 2012; 7 5 537 548
12. Dwyer J. R., Sever N., Carlson M., Nelson S. F., Beachy P. A., Parhami F. Oxysterols are novel activators of the Hedgehog signaling pathway in pluripotent mesenchymal cells. J Biol Chem: 2007; 282 12 8959 8968
13. Nachtergaele S., Mydock L. K., Krishnan K., et al. Oxysterols are allosteric activators of the oncoprotein Smoothened. Nat Chem Biol: 2012; 8 2 211 220
14. Yoon J. H., Higuchi H., Werneburg N. W., Kaufmann S. H., Gores G. J. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology: 2002; 122 4 985 993
15. Yoon J. H., Canbay A. E., Werneburg N. W., Lee S. P., Gores G. J. Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis. Hepatology: 2004; 39 3 732 738
16. Andersen J. B., Thorgeirsson S. S. Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol: 2012; 28 3 266 272
17. Ong C. K., Subimerb C., Pairojkul C., et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet: 2012; 44 6 690 693
18. Chan-On W., Nairismägi M. L., Ong C. K., et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet: 2013; 45 12 1474 1478
19. Jiao Y., Pawlik T. M., Anders R. A., et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet: 2013; 45 12 1470 1473
20. Gao Q., Zhao Y. J., Wang X. Y., et al. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. Gastroenterology: 2014; 146 5 1397 1407
21. Sia D., Hoshida Y., Villanueva A., et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology: 2013; 144 4 829 840
22. Andersen J. B., Spee B., Blechacz B. R., et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology: 2012; 142 4 1021 1031, e15
23. Sia D., Tovar V., Moeini A., Llovet J. M. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene: 2013; 32 41 4861 4870
24. Khan S. A., Thomas H. C., Toledano M. B., Cox I. J., Taylor-Robinson S. D. p53 Mutations in human cholangiocarcinoma: a review. Liver Int: 2005; 25 4 704 716
25. Tannapfel A., Sommerer F., Benicke M., et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut: 2003; 52 5 706 712
26. Kobayashi S., Werneburg N. W., Bronk S. F., Kaufmann S. H., Gores G. J. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology: 2005; 128 7 2054 2065
27. Park J., Tadlock L., Gores G. J., Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology: 1999; 30 5 1128 1133
28. Taniai M., Grambihler A., Higuchi H., et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res: 2004; 64 10 3517 3524
29. Isomoto H., Kobayashi S., Werneburg N. W., et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology: 2005; 42 6 1329 1338
30. Isomoto H., Mott J. L., Kobayashi S., et al. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology: 2007; 132 1 384 396
31. Genovese M. C., Fleischmann R., Furst D., et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis: 2014; 73 9 1607 1615
32. Tanaka Y., Martin Mola E. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Ann Rheum Dis: 2014; 73 9 1595 1597
33. Abulwerdi F., Liao C., Liu M., et al. A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther: 2014; 13 3 565 575
34. Abulwerdi F. A., Liao C., Mady A. S., et al. 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation. J Med Chem: 2014; 57 10 4111 4133
35. Yu C., Bruzek L. M., Meng X. W., et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene: 2005; 24 46 6861 6869
36. Hofmann J. J., Zovein A. C., Koh H., Radtke F., Weinmaster G., Iruela-Arispe M. L. Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndrome. Development: 2010; 137 23 4061 4072
37. Ishimura N., Bronk S. F., Gores G. J. Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology: 2005; 128 5 1354 1368
38. Fan B., Malato Y., Calvisi D. F., et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest: 2012; 122 8 2911 2915
39. Sekiya S., Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest: 2012; 122 11 3914 3918
40. Zender S., Nickeleit I., Wuestefeld T., et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell: 2013; 23 6 784 795
41. Morell C. M., Strazzabosco M. Notch signaling and new therapeutic options in liver disease. J Hepatol: 2014; 60 4 885 890
42. Sirica A. E. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol: 2008; 14 46 7033 7058
43. Kiguchi K., Carbajal S., Chan K., et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res: 2001; 61 19 6971 6976
44. Graham R. P., Barr Fritcher E. G., Pestova E., et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol: 2014; 45 8 1630 1638
45. Lubner S. J., Mahoney M. R., Kolesar J. L., et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol: 2010; 28 21 3491 3497
46. Philip P. A., Mahoney M. R., Allmer C., et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol: 2006; 24 19 3069 3074
47. Voss J. S., Holtegaard L. M., Kerr S. E., et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol: 2013; 44 7 1216 1222
48. Borad M. J., Champion M. D., Egan J. B., et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet: 2014; 10 2 e1004135
49. Comoglio P. M., Giordano S., Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov: 2008; 7 6 504 516
50. Appleman L. J. MET signaling pathway: a rational target for cancer therapy. J Clin Oncol: 2011; 29 36 4837 4838
51. Ross J. S., Wang K., Gay L., et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist: 2014; 19 3 235 242
52. Gu T. L., Deng X., Huang F., et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS ONE: 2011; 6 1 e15640
53. Saborowski A., Saborowski M., Davare M. A., Druker B. J., Klimstra D. S., Lowe S. W. Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci U S A: 2013; 110 48 19513 19518
54. Davare M. A., Saborowski A., Eide C. A., et al. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc Natl Acad Sci U S A: 2013; 110 48 19519 19524
55. Arai Y., Totoki Y., Hosoda F., et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology: 2014; 59 4 1427 1434
56. Wu Y. M., Su F., Kalyana-Sundaram S., et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov: 2013; 3 6 636 647
57. Guagnano V., Kauffmann A., Wöhrle S., et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov: 2012; 2 12 1118 1133
58. Escudier B., Grünwald V., Ravaud A., et al. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer. Clin Cancer Res: 2014; 20 11 3012 3022
59. Grassian A. R., Pagliarini R., Chiang D. Y. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol: 2014; 30 3 295 302
60. Kipp B. R., Voss J. S., Kerr S. E., et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol: 2012; 43 10 1552 1558
61. Wang P., Dong Q., Zhang C., et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene: 2013; 32 25 3091 3100
62. Rohle D., Popovici-Muller J., Palaskas N., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science: 2013; 340 6132 626 630
63. Wang F., Travins J., DeLaBarre B., et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science: 2013; 340 6132 622 626
64. Xu R. F., Sun J. P., Zhang S. R., et al. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomed Pharmacother: 2011; 65 1 22 26
65. Meng F., Henson R., Lang M., et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology: 2006; 130 7 2113 2129
66. Sheppard K., Kinross K. M., Solomon B., Pearson R. B., Phillips W. A. Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog: 2012; 17 1 69 95
67. Liu N., Rowley B. R., Bull C. O., et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Mol Cancer Ther: 2013; 12 11 2319 2330
68. Wallin J. J., Edgar K. A., Guan J., et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther: 2011; 10 12 2426 2436
69. Costello B. A., Borad M. J., Qi Y., et al. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Invest New Drugs: 2014; 32 4 710 716
70. Ma X., Ezzeldin H. H., Diasio R. B. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs: 2009; 69 14 1911 1934
71. Sirica A. E. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol: 2012; 9 1 44 54
72. DeClerck Y. A. Desmoplasia: a response or a niche? Cancer Discov: 2012; 2 9 772 774
73. Ling H., Roux E., Hempel D., et al. Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. PLoS ONE: 2013; 8 1 e54499
74. Pinlaor S., Prakobwong S., Hiraku Y., Pinlaor P., Laothong U., Yongvanit P. Reduction of periductal fibrosis in liver fluke-infected hamsters after long-term curcumin treatment. Eur J Pharmacol: 2010; 638 1-3 134 141
75. Mertens J. C., Fingas C. D., Christensen J. D., et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res: 2013; 73 2 897 907
76. Olive K. P., Jacobetz M. A., Davidson C. J., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science: 2009; 324 5933 1457 1461
77. Garber K. Stromal depletion goes on trial in pancreatic cancer. J Natl Cancer Inst: 2010; 102 7 448 450
78. Clapéron A., Mergey M., Aoudjehane L., et al. Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. Hepatology: 2013; 58 6 2001 2011
79. Fingas C. D., Bronk S. F., Werneburg N. W., et al. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology: 2011; 54 6 2076 2088
80. Fingas C. D., Mertens J. C., Razumilava N., Bronk S. F., Sirica A. E., Gores G. J. Targeting PDGFR-β in cholangiocarcinoma. Liver Int: 2012; 32 3 400 409
81. Wiedmann M. W., Mössner J. Molecular targeted therapy of biliary tract cancer-results of the first clinical studies. Curr Drug Targets: 2010; 11 7 834 850
82. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med: 2012; 366 26 2517 2519